Skip to content

Positive Airway Pressure Therapy in Diastolic Heart Failure and Obstructive Sleep Apnea – PARADISE Trial Pilot Study

Positive Airway Pressure Therapy in Diastolic Heart Failure and Obstructive Sleep Apnea – PARADISE Trial Pilot Study - PARADISE Pilot

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00000489
Enrollment
40
Registered
2010-07-20
Start date
2010-08-02
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I50.19 G47.31

Interventions

Group 1: Automatic, continuous positive airway pressure (APAP/CPAP) for 6 months

Sponsors

Kardiologische Klinik, Herz- und Diabeteszentrum NRW, Universitätsklinik der Ruhr-Universität Bochum
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: - HFPEF, diagnosed according to current ESC guidelines - Stable conditions for at least 6 weeks prior to inclusion period - Pre-diagnosed moderate to severe Obstructive Sleep Apnoeas with an AHI of = 15/h - no electrical devices implantation within the last 6months - pacing time < 10% of total

Exclusion criteria

Exclusion criteria: - Myocardial infarction, cardiothoracic surgery, stroke, or onset of atrial fibrillation within the last 3 months - changes in cardiovascular medication within the last6 weeks - uncontrolled arterial hypertension (resting BP > 160/95mmHg on two consecutive days) - pregnancy - COPD (FEV1/VC 45mmHg and/or pO2 I.° - HCM, HOCM - untreated or theraqpy refractory restless legs syndrome - ongoing ventilation therapy

Design outcomes

Primary

MeasureTime frame
Improvement of diastolic function (e/E’) with TDI after 2-4 weeks, 3 months, and 6 months

Secondary

MeasureTime frame
at follow-up (2-4 weeks, 3 months, and 6months): - Changes in functional NYHA-class - Changes in NT-proBNP - Changes in Cardiopulmonary exercise capacity (VO2 peak, predicted VO2 peak, VO2 AT) - Changes in walk distance within 6 minutes - Changes in left atrial diameter (LAD), Changes in intraventricular and posterior wall thickness - Changes in Epworth Sleepiness Scale (ESS), and Minnesota Living With Heart Failure Score (MLWHF)

Countries

Germany

Contacts

Public ContactThomas Bitter

Kardiologische Klinik, Herz- und Diabeteszentrum NRW, Universitätsklinik der Ruhr-Universität Bochum

akleemeyer@hdz-nrw.de05731 971258

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026